Table 1.

Baseline participant characteristics (intention-to-treat analysis set)

	Exenatide (N = 58)	Placebo (N = 24)	Total (N = 82)
Age, years, mean ± SD (min, max)	15 ± 1.9 (11, 17)	16 ± 1.7 (12, 17)	15 ± 1.8 (11, 17)
Female sex	31 (53.4)	17 (70.8)	48 (58.5)
Region
Europe	8 (13.8)	4 (16.7)	12 (14.6)
Middle East	2 (3.4)	1 (4.2)	3 (3.7)
North America	35 (60.3)	17 (70.8)	52 (63.4)
South America	13 (22.4)	2 (8.3)	15 (18.3)
Race
White	23 (39.7)	12 (50.0)	35 (42.7)
Black or African American	17 (29.3)	8 (33.3)	25 (30.5)
Asian	2 (3.4)	1 (4.2)	3 (3.7)
Native Hawaiian or other Pacific Islander	0	0	0
American Indian or Alaska Native	4 (6.9)	1 (4.2)	5 (6.1)
Other	12 (20.7)	2 (8.3)	14 (17.1)
Hispanic or Latino ethnic group
Yes	25 (46.3)	8 (38.1)	33 (44.0)
No	29 (53.7)	13 (61.9)	42 (56.0)
Duration of diabetes, years, mean ± SD	2 ± 2	3 ± 2	2 ± 2
Body weight, kg, mean ± SD	102.2 ± 30.1	96.7 ± 22.7	100.6 ± 28.1
BMI, kg/m2, mean ± SD	36.86 ± 9.28	35.14 ± 6.58	36.36 ± 8.57
Glycated hemoglobin, %, mean ± SD (mmol/mol)	8.1 ± 1.2 (65.0)	8.3 ± 1.5 (67.2)	8.2 ± 1.3 (66.1)
Fasting plasma glucose, mg/dL, mean ± SD	165.0 ± 59.3	170.5 ± 60.4	166.6 ± 59.3
Prior antihyperglycemia treatment naive	8 (13.8)	2 (8.3)	10 (12.2)
Prior antihyperglycemia drug use
Metformin only	22 (37.9)	11 (45.8)	33 (40.2)
Insulin only	6 (10.3)	1 (4.2)	7 (8.5)
Insulin and metformin	21 (36.2)	10 (41.7)	31 (37.8)
Metformin and a sulfonylurea	1 (1.7)	0	1 (1.2)

Data are n (%) unless otherwise indicated. Baseline was defined as the last nonmissing assessment (scheduled or unscheduled) on or prior to the first dose of the randomized study medication. Percentages were calculated from the number of participants in the analysis set with nonmissing data, by treatment group and in total. max, maximum; min, minimum.